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Landmark experiments in the 1920s showed that capsule switching is critical for Streptococcus pneumonia
survival. Further studies demonstrated that capsule ‘‘transformation’’ occurs via DNA uptake. In this issue of
Cell Host and Microbe, Bikard et al. (2012) show that CRISPR-Cas systems inhibit DNA uptake, selecting for
the outgrowth of CRISPR-defective pneumococci.To take up DNA or not to take up DNA—
that is the question. Each microbe must
balance the need to acquire newbeneficial
traitsbyhorizontal gene transfer (HGT)with
the need to prevent the entry of genetic
elements that impose fitness costs (Levin,
2010) (Figure 1). One system allowing
microbes to limit the entry of costly genetic
elements is the CRISPR-Cas adaptive
immune system found in many bacteria
and archaea (Wiedenheft et al., 2012).
CRISPR-Cas systems have been shown
to inhibit DNA uptake by phage infection,
plasmidconjugation, andartificial transfor-
mation (Barrangou et al., 2007; Marraffini
and Sontheimer, 2008; Wiedenheft et al.,
2012). For the 90% of archaea and 50%
of bacteria that maintain CRISPR-Cas
systems (Wiedenheft et al., 2012), there
are apparently more benefits to inhibiting
DNA uptake than to promoting it.
Recognized in microbial genomes as
cassettes of clustered regularly inter-
spaced short palindromic repeats
(CRISPR) and CRISPR-associated (Cas)
genes, CRISPR-Cas systems have been
the subject of a number of recent studies
(Wiedenheft et al., 2012). These investiga-
tions have shown that when a microbial
genome containing CRISPR-Cas survives
an initial phage or plasmid infection, it can
acquire a short DNA fragment, known as a
‘‘spacer,’’ from the invading virus or plas-
mid. Once transcribed and processed,
this CRISPR spacer is used to guide a
complex of Cas proteins to destroy in-
vading genetic elements that contain
matching DNA sequences (Wiedenheft
et al., 2012).
The decision of whether or not to main-
tain a CRISPR-Cas system depends ona balance of factors that are just begin-
ning to be understood and quantified.
Enterococcus faecalis represents an in-
teresting example of how this bacterial
calculus has been affected by the antibi-
otic era. E. faecalis is a highly evolved
inhabitant of the gastrointestinal (GI)
tracts of animals, from insects to man.
In the complex milieu of the GI tract, there
is a high probability of encountering en-
terococcal phages and potentially other
parasitic elements, making CRISPR-
mediated defense highly beneficial. How-
ever, CRISPR-Cas systems also con-
stitute an impediment to the entry of
antibiotic resistance genes conveyed by
mobile elements, a barrier that is increas-
ingly costly in the antibiotic era. As a
result, a recent genomic study found
that antibiotic resistance is concentrated
in E. faecalis strains that have lost
CRISPR-Cas defense (Palmer and Gil-
more, 2010). This loss of CRISPR-Cas
has likely had a profound effect on
hospital-adapted E. faecalis strains,
which now have genomes about 25%
larger than those of commensal strains,
and are replete with plasmids, phages,
pathogenicity islands, and other elements
(Palmer et al., 2012). Undoubtedly, this
rapid evolution of hospital isolates has
been accompanied by fitness costs in
a competitive environment, but in a hospi-
talized patient treated with antibiotics,
colonization by resistant E. faecalis is
largely noncompetitive.
As Bikard et al. (2012) note,
S. pneumoniae naturally lack CRISPR-
Cas loci, whereas other closely related,
naturally transformable oral streptococci
possess CRISPR-Cas. Given the historicCell Host & Microbe 12and landmark demonstrations by Griffith
(1928) and Avery et al. (1944) showing
the importance of transformation for
immune escape by S. pneumoniae, it
was of interest to determine whether
selection for escape mutants is sufficient
to explain the absence of CRISPR-Cas
in S. pneumoniae. Since no known
S. pneumoniae strains contain CRISPR-
Cas systems, Bikard et al. (2012) grafted
a functional CRISPR locus into
S. pneumoniae from the related species,
S. pyogenes. They also engineered a
S. pneumoniae DNA donor to contain a
sequence targeted by a S. pyogenes
CRISPR spacer. This CRISPR-Cas target
sequence was placed adjacent to a
selectable antibiotic resistance marker.
Showing that CRISPR-Cas blocks trans-
formation in vitro, Bikard et al. (2012)
found that the transplanted CRISPR-Cas
system prevents uptake of the resistance
marker by S. pneumoniae, but only when
the donor harbors the adjacent perfect
match to the CRISPR spacer. Using very
high levels of donor DNA, the investiga-
tors were able to obtain a few antibiotic
resistant transformants. Yet, these resis-
tant transformants had loss-of-function
mutations in the CRISPR-Cas system or
in the target sequence.
Having quantified the effect of CRISPR-
Cas as an obstacle to transformation
in vitro, it was then of interest to determine
whether CRISPR-Cas would block the
capsule switching observed by Griffith
(1928) in vivo. Thus, Bikard et al. (2012) in-
serted a new spacer element identical in
sequence to a portion of a S. pneumoniae
capsule gene into the grafted CRISPR
array. The experiments of Griffith (1928), August 16, 2012 ª2012 Elsevier Inc. 125
Figure 1. CRISPR Blocks Rough-to-Smooth Transformation In Vivo
(Top row) The seminal 1928 experiments of Griffith (1928), who found that injection of a rough (unencap-
sulated) strain of S. pneumoniae rarely killed mice (top left), whereas injection of a smooth (encapsulated)
strain did, and the smooth strain could be recovered from the dead mouse. Injection of heat-killed encap-
sulated bacteria (gray smooth) did not kill mice, but the combination of live rough S. pneumoniae together
with heat-killed encapsulatedS. pneumoniae established a productive infection that killed themice.More-
over, when the bacteria recovered from the dead mice were cultured, they had ‘‘transformed’’ from rough
to smooth (Griffith, 1928). In the present work (Bikard et al. (2012) showed that if the rough strain carried
a functional CRISPR-Cas system that was designed to target a capsule gene, the transformation to
smooth, virulent S. pneumoniae was blocked. Further, these investigators showed that when they forced
the experiment using larger doses of bacteria, one mouse died and smooth bacteria were in fact recov-
ered. These bacteria had mutated their CRISPR-Cas system, rendering it nonfunctional and unable to
block the uptake of capsular DNA.
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with a mixture of heat-killed encapsulated
S. pneumoniae and live, avirulent un-
encapsulated, S. pneumoniae. Differing
from Griffth’s setup, the avirulent mice
were now CRISPR+ and loaded with a
spacer from a capsule gene. Unlike
Griffith’s experiments, the mice survived,
showing that CRISPR-Cas represents a
barrier to capsule switching. However,
using higher levels of CRISPR-positive re-
cipients and dead encapsulated donors,
a mouse was killed. As in the in vitro
experiments, the escape mutant that
acquired the capsular genes and killed
the mouse lacked a functional CRISPR-
Cas system. This implies that selection126 Cell Host & Microbe 12, August 16, 2012during the course of S. pneumoniae infec-
tion is strong enough to spur the out-
growth of CRISPR-Cas defective mutants
and may explain why S. pneumoniae
natively lack what appears to be a highly
useful system to keep foreign DNA out.
For hospital adapted E. faecalis and
S. pneumoniae, the need for genomic
plasticity may mean that the benefits of
facile DNA uptake offset the fitness
costs associated with lacking CRISPR-
Cas’ defenses. More generally, one can
hypothesize that CRISPR-Cas’ frequency
in a species is shaped by the probability
that a species encounters deleterious
foreign DNA. When incoming DNA is
mainly harmful to the cell (e.g., lyticª2012 Elsevier Inc.viruses), maintaining CRISPR-Cas offers
a large selective advantage. Conversely,
when microbes require foreign DNA to
survive (e.g., under antibiotic targeting),
CRISPR-Cas’ inhibition of horizontal
gene transfer is deleterious. Of course,
this tug-of-war selecting for and against
CRISPR-Cas may be oversimplified.
Some microbes might maintain CRISPR-
Cas loci even when HGT is beneficial. As
in E. coli (Westra et al., 2010), organisms
may do so by repressing their CRISPR-
Cas systems using genetic switches.
When HGT suddenly becomes harmful,
these silent loci could then be switched
on to reapCRISPR-Cas’ benefits. Awhole
circuitry for modulating CRISPR-Cas im-
munity may be ripe for discovery.REFERENCES
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